Clinical Trial Update: Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating methylphenidate (Ritalin) for antiasthenic effect in palliative-care cancer patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Ritalin (methylphenidate)

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Asthenia, Neoplasms | Phase 3 | Status: TERMINATED